CV Sciences (CVSI) EBITDA (2011 - 2026)

CV Sciences has disclosed EBITDA across 16 years of filings, most recently posting -$301000.0 for Q2 2026.

• In Q2 2026, EBITDA fell 129.77% year-over-year to -$301000.0; the TTM figure through Jun 2026 stood at -$969000.0 (up 12.47% YoY), while the FY2025 annual figure was -$470000.0, up 78.54% from the prior year.
• EBITDA came in at -$301000.0 for Q2 2026 at CV Sciences, up from -$318000.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of $5.8 million in Q1 2023 to a low of -$2.3 million in Q2 2022.
• Average EBITDA over 5 years is -$375888.9, with a median of -$510000.0 recorded in 2023.
• Year-over-year, EBITDA surged 480.33% in 2023 and plunged 2990.91% in 2026.
• Over 5 years, EBITDA stood at -$2.1 million in 2022, then jumped by 58.16% to -$889000.0 in 2023, then rose by 27.33% to -$646000.0 in 2024, then soared by 88.39% to -$75000.0 in 2025, then slumped by 301.33% to -$301000.0 in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$301000.0 in Q2 2026, -$318000.0 in Q1 2026, and -$75000.0 in Q4 2025.